Fan Yadong, Wang Ying, Yu Shuang, Chang Jun, Yan Yiqi, Wang Yiyang, Bian Yuhong
School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, No.10 PoYangHu Road, JingHai, District, Tianjin, 301617, People's Republic of China.
Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Chin Med. 2021 Jul 28;16(1):67. doi: 10.1186/s13020-021-00478-3.
Exaggerated immune response and cytokine storm are accounted for the severity of COVID-19, including organ dysfunction, especially progressive respiratory failure and generalized coagulopathy. Uncontrolled activation of complement contributes to acute and chronic inflammation, the generation of cytokine storm, intravascular coagulation and cell/tissue damage, which may be a favorable target for the treatment of multiple organ failure and reduction of mortality in critically ill patients with COVID-19. Cytokine storm suppression therapy can alleviate the symptoms of critically ill patients to some extent, but as a remedial etiological measure, its long-term efficacy is still questionable. Anti-complement therapy has undoubtedly become an important hotspot in the upstream regulation of cytokine storm. However, chemosynthetic complement inhibitors are expensive, and their drug resistance and long-term side effects require further investigation. New complement inhibitors with high efficiency and low toxicity can be obtained from natural products at low development cost. This paper puts forward some insights of the development of natural anti-complement products in traditional Chinese medicine, that may provide a bright perspective for suppressing cytokine storm in critically ill patients with COVID-19.
过度的免疫反应和细胞因子风暴是导致COVID-19严重程度的原因,包括器官功能障碍,尤其是进行性呼吸衰竭和全身性凝血障碍。补体的失控激活会导致急性和慢性炎症、细胞因子风暴的产生、血管内凝血和细胞/组织损伤,这可能是治疗COVID-19重症患者多器官功能衰竭和降低死亡率的一个有利靶点。细胞因子风暴抑制疗法在一定程度上可以缓解重症患者的症状,但作为一种补救性病因治疗措施,其长期疗效仍值得怀疑。抗补体疗法无疑已成为细胞因子风暴上游调控的一个重要热点。然而,化学合成补体抑制剂价格昂贵,其耐药性和长期副作用需要进一步研究。从天然产物中可以以较低的开发成本获得高效低毒的新型补体抑制剂。本文提出了一些关于中药天然抗补体产品开发的见解,这可能为抑制COVID-19重症患者的细胞因子风暴提供一个光明的前景。